It used to focus on the research and development of new drugs, but it once faced a crisis of running out of funds. For this reason, Taibao Biomedical decided to give it a go and strive for transformation. Locking in the second development route of OEM production, how does Taibao create a competitive production line and attract cooperation from international customers?
In September this year, Taibao Biomedical announced that it had acquired an exclusive technology transfer from Harvard University and would cooperate with Arlene Sharpe, an authority on immunotherapy india telegram and Harvard professor, to develop a targeted cell therapy platform for autoimmune diseases. This makes Taibao a rare Taiwanese partner of Harvard in the field of medical technology transfer.
The cooperation between the two parties is based on Harvard's immune checkpoint technology and is applied in Taibao's cell development and manufacturing services (CDMO) to create cell drugs that are like targeted drugs. "Professor Sharp can only cooperate with us for cell therapy at immune checkpoints." Taibao Chief Operating Officer Yang Junyao said that this is the application of Harvard's technology in non-cancer and the exclusive cooperation relationship with Taibao.
- Board index
- All times are UTC
- Delete cookies
- Contact us